INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Clinical Review on Mucormycosis

Sonkamble Sumed, Devshatwar Radhika*, Jamadar Amrata, Kamshette Arati, Akuch Sandhya, Survase Mohini

Godavari Institute Of Pharmacy Kolpa, Latur- 413512, Maharashtra, India.

ARTICLE INFO

Published: 07 April. 2025
Keywords:
Mucormycosis, Rhizopus, Fungal Infection, Immunocompromised, Diabetes, Diagnosis, Treatment Mucormycosis, Amphotericin B, Prognosis.
DOI:
10.5281/zenodo.15166601

ABSTRACT

Is a rare but life-threatening fungal infection caused by fungi belonging to the order Mucorales, predominantly Rhizopus, Mucor, Rhizomucor, and Lichtheimia. The infection is characterized by rapid tissue necrosis and has a high mortality rate if not diagnosed and treated promptly. Mucormycosis primarily affects immunocompromised individuals, including those with uncontrolled diabetes mellitus, hematological malignancies, solid organ transplants, and those undergoing prolonged corticosteroid therapy. The disease typically manifests in four clinical forms: rhino-orbital-cerebral, pulmonary, gastrointestinal, and cutaneous. Rhino-orbital-cerebral mucormycosis is the most common and is often associated with diabetic ketoacidosis, where the fungus invades the sinuses, spreading to the orbit and brain. Early diagnosis relies on clinical suspicion, radiological imaging, histopathological examination, and microbiological cultures. Treatment involves a combination of antifungal therapy, usually with liposomal amphotericin B, and, when feasible, surgical debridement of necrotic tissue. Despite aggressive treatment, the prognosis remains poor, particularly in patients with extensive disease or underlying immunocompromise. Preventive strategies focus on controlling predisposing factors, such as optimal management of diabetes and minimizing the use of immunosuppressive agents. The increasing incidence of mucormycosis, particularly in the context of the COVID-19 pandemic, highlights the need for greater awareness, early detection, and timely intervention. This review article presents the current statistics, the causes of this infection in the human body, and its diagnosis with available recent therapies through recent databases collected from several clinics and agencies. The diagnosis and identifcation of the infection were made possible through various latest medical techniques such as computed tomography scans, direct microscopic observations, MALDI-TOF mass spectrometry, serology, molecular assay, and histopathology.

***Corresponding Author:** Devshatwar Radhika
Address: Godavari Institute of Pharmacy Kolpa, Latur- 413512, Maharashtra, India.
Email ✉: devshatwarradhika@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Mucormycosis, also known as zygomycosis, is a rare but serious fungal infection caused by a group of molds known as mucormycetes. These fungi are typically found in decaying organic matter such as soil, leaves, compost, and decaying fruit. When the spores of these molds are inhaled or come into contact with broken skin, they can lead to severe infections, particularly in individuals with compromised immune systems. Mucormycosis predominantly affects people who are immunocompromised, such as those with uncontrolled diabetes, cancer, organ transplants, or those taking immunosuppressive medications. It can also affect individuals with severe trauma or burns, or those with chronic conditions like kidney failure.

The infection can manifest in several different forms, depending on the area of the body that is affected:

- Rhinocerebral mucormycosis: The most common form, which involves the sinuses and can spread to the brain, causing severe complications.
- Pulmonary mucormycosis: Affects the lungs, often seen in patients with neutropenia (low white blood cell count) or those on immunosuppressive treatments.
- Cutaneous mucormycosis: Involves the skin and typically occurs after trauma, surgery, or burns. - Gastrointestinal mucormycosis: Affects the gastrointestinal tract and is rare but can be seen in infants or immunocompromised patients.
- Disseminated mucormycosis: When the infection spreads throughout the body, often affecting multiple organs, and is particularly fatal without prompt treatment.

Symptoms of mucormycosis can vary based on the site of infection but may include fever, headache, facial swelling, black lesions (especially in the nose or mouth), chest pain, difficulty breathing, and gastrointestinal discomfort. Because of its rapid progression and the need for immediate treatment, mucormycosis is considered a medical emergency.

Underlying conditions associated with mucormycosis:

Mucormycosis has been associated with various underlying conditions that predispose an individual to the infection. Some of these factors include diabetes, neutropenia, organ or stem cell transplantation, trauma and burns, hematological disorders, steroidal use, metabolic acidosis, intravenous drug usage, renal insufficiency, broad-spectrum antibiotics, increase in iron in the system, malnutrition, usage of voriconazole (Fig. 2) (Dantas et al., 2021; Sarvestani et al., 2013; Shariati et al., 2020; Suganya et al., 2019). A previous study from Europe (Skiada et al., 2011) showed that, the most significant underlying causes were hematological malignancies, while it was diabetes mellitus in India (Chakrabarti et al., 2009), Iran (Dolatabadi et al., 2018), Middle East, North Africa (Stemler et al., 2020) and Mexico (Corzo-Leon ´ et al., 2018). Among the different forms of mucormycosis, ROCM has been concomitant with the presence of diabetes. The cutaneous form was more prominent in individuals with trauma, and organ transplant was related to the pulmonary, gastrointestinal and disseminated type. In addition, underlying hematological malignancies were present in disseminated type and neutropenia in the pulmonary form (Jeong et al., 2019). Mucormycosis occurs mainly in individuals with uncontrolled diabetes, and this is because the innate immunity in these individuals, impacts the polymorphonuclear phagocytes to

destroy the fungi. In patients with diabetes, the sinus was the most affected area followed by the pulmonary areas (Rammaert et al., 2012). Individuals with hematological malignancies were also predisposed to mucormycosis during the neutropenia phase of the ailment.



Classification of mucormycosis

Mucormycosis, also known as zygomycosis, is a rare but serious fungal infection caused by molds in the order Mucorales. The classification of mucormycosis can be understood from both a clinical and a microbiological perspective. Below is a breakdown of the classification based on these two frameworks:

1. Clinical Classification of Mucormycosis

Mucormycosis can affect various parts of the body, leading to different clinical presentations. Based on the site of infection, mucormycosis is classified into the following types: a. Rhinocerebral Mucormycosis

- Common in diabetic ketoacidosis (DKA) and immunocompromised individuals.
- The infection often starts in the nasal passages and sinuses and can extend to the brain, leading to necrosis of the tissue.
- Symptoms: Fever, headache, facial swelling, sinus pain, black necrotic tissue in the nasal cavity.

b. Pulmonary Mucormycosis

- Involves the lungs and often occurs in immunocompromised patients, particularly those with hematological malignancies, organ transplant recipients, and those on immunosuppressive therapy.
- Symptoms: Cough, hemoptysis, pleuritic chest pain, shortness of breath, and fever. c. Gastrointestinal Mucormycosis
- More commonly seen in neonates, premature infants, and immunocompromised individuals.
- Often presents with abdominal pain, vomiting, diarrhea, and signs of sepsis.

- Mortality is high, especially when not diagnosed early.

Cutaneous Mucormycosis

- Infection of the skin, usually following trauma or burns.
- Symptoms: Painful erythematous lesions that may develop into necrotic ulcers.
- Can be seen in patients with diabetes, intravenous drug users, or in those who have had surgery or wounds.

Renal Mucormycosis

- Mucormycosis can also involve the kidneys, typically seen in patients with diabetes mellitus or those who are immunosuppressed.
- Symptoms: Fever, flank pain, and possible renal failure.

Disseminated Mucormycosis

- Mucormycosis may spread from a local site (like the sinuses or lungs) to other organs, including the heart, brain, gastrointestinal tract, and kidneys.
- Symptoms are variable and depend on the organs affected.
- This is the most severe form and is often seen in severely immunocompromised patients.

2. Microbiological Classification (Fungal Taxonomy)

The causative organisms of mucormycosis belong to the Mucorales order, within the class Zygomycetes. The major genera that cause mucormycosis include: a. Rhizopus

- The most common cause of mucormycosis.
- Species such as Rhizopus oryzae are the most frequently implicated. b. Mucor
- Another major genus responsible for mucormycosis.
- Species like Mucor racemosus are often isolated in clinical cases.

Lichtheimia (formerly Absidia)

 Species such as Lichtheimia corymbifera are important pathogens in mucormycosis. d. Cunninghamella
 Less common but still implicated in infections, especially in immunocompromised patients.

Syncephalastrum

 Occasionally causes mucormycosis, particularly in patients with hematologic malignancies or those undergoing organ transplantation.

Fig.1 Structures of Rhizopus



Fig.2 Structure of Rhizopus

3. Risk Factors for Mucormycosis

Mucormycosis predominantly affects immunocompromised individuals. Common risk factors include:

- Diabetes mellitus, especially in cases of diabetic ketoacidosis (DKA).
- Hematological malignancies (leukemia, lymphoma).
- Organ transplantation (kidney, liver, heart).
- Immunosuppressive therapy (e.g., corticosteroids, TNF inhibitors).
- Severe burns or trauma.
- Neutropenia (due to chemotherapy or other conditions).
- Chronic kidney disease and patients on dialysis.

4. Diagnostic Classification

Diagnosis of mucormycosis typically involves a combination of clinical, microbiological, and imaging studies:

- Direct microscopy (KOH or calcofluor white stain) can identify broad, non-septate hyphae with right-angle branching.
- Culture on Sabouraud dextrose agar or other selective fungal media can help isolate the causative organism.
- Histopathology may show invasion of blood vessels by hyphae, a hallmark of mucormycosis.
- PCR and other molecular techniques can also be used for identification of species.

5. Treatment Classification

Treatment generally involves a combination of: Surgical debridement of necrotic tissue.

- Antifungal therapy, primarily with liposomal amphotericin B or posaconazole (depending on the species).
- Control of underlying risk factors (e.g., improving glycemic control in diabetic patien

Sign and Symptom

The signs and symptoms of mucormycosis vary depending on the site of infection, the underlying health conditions of the patient, and the severity of the disease. Mucormycosis can affect different parts of the body, including the sinuses, lungs, skin, gastrointestinal tract, and brain. Below is an overview of the typical signs and symptoms of

mucormycosis based on the affected organ/system:

1. Rhinocerebral Mucormycosis

This is the most common form of mucormycosis, primarily affecting the sinuses and brain. It is often seen in diabetic patients (especially those with diabetic ketoacidosis) and immunocompromised individuals.

Signs and Symptoms:

Nasal congestion and discharge (often purulent or bloody).

- Black necrotic tissue in the nasal cavity.
- Pain or pressure in the sinuses or face.
- Facial swelling or cellulitis around the eyes and cheeks.
- Headache, often severe.
- Pain behind the eyes or orbital pain.
- Proptosis (bulging eyes) and eyelid swelling.
- Mental status changes or confusion (if the infection spreads to the brain).

2. Pulmonary Mucormycosis

This form affects the lungs and is typically seen in patients with conditions such as hematological malignancies, organ transplant recipients, neutropenic patients, and those receiving immunosuppressive therapy.

Signs and Symptoms:

- Cough, which may be productive of bloody sputum (hemoptysis).
- Shortness of breath (dyspnea).
- Chest pain, which may be pleuritic (worsens with breathing or coughing).
- Fever and chills.
- Fatigue or malaise.
- Hypoxia (low blood oxygen levels).
- Worsening respiratory failure if the infection becomes severe.

3. Gastrointestinal Mucormycosis

Involvement of the gastrointestinal (GI) tract is rare but can be seen, particularly in neonates, premature infants, and severely immunocompromised individuals.

Signs and Symptoms:

- Abdominal pain (often severe and localized).
- Nausea, vomiting, and diarrhea.
- Gastrointestinal bleeding (in severe cases, leading to melena or hematemesis). - Sepsis: High fever, hypotension, and tachycardia due to systemic infection.
- Distention or bloating of the abdomen, which may indicate bowel obstruction.
- Signs of peritonitis (inflammation of the peritoneal lining) if the infection spreads to the peritoneum.

4. Cutaneous Mucormycosis

Cutaneous mucormycosis typically results from direct inoculation of spores through trauma, surgery, or burns. It is often seen in diabetic patients or those with skin wounds.

Signs and Symptoms:

- Painful, erythematous (red) skin lesions.
- Swelling and warmth around the infected area.
- Ulceration of the skin with possible necrosis (black, dead tissue).
- Eschar formation (a dark, dry, necrotic patch of skin).
- Fever and systemic symptoms of infection.
- Rapid tissue necrosis leading to gangrene in severe cases.

5. Renal Mucormycosis

Though rare, mucormycosis can also involve the kidneys, particularly in patients with diabetes, chronic kidney disease, or those on dialysis.

Signs and Symptoms:

- Flank pain.
- Fever and chills.
- Hematuria (blood in the urine).
- Renal failure (can occur in severe cases).
- Elevated serum creatinine and blood urea nitrogen (BUN), indicating kidney dysfunction.

Risk factors: -

The development of mucormycosis is closely linked to several risk factors that primarily involve immune suppression and disruption of normal host defenses. These factors make individuals more susceptible to the fungal infection by impairing their ability to prevent fungal spores (conidia) from invading tissues and causing disease. Below are the key risk factors for mucormycosis:

1. Diabetes Mellitus

Diabetes, especially in patients with poorly controlled blood sugar levels or diabetic ketoacidosis (DKA), is one of the most significant risk factors for mucormycosis.

- High blood glucose levels and the acidotic state (from DKA) create a favorable environment for the growth of Mucorales fungi.
- Impaired neutrophil function in diabetic patients also hinders the immune system's ability to fight off fungal infections effectively.
- Commonly affects rhinocerebral mucormycosis.

2. Immunocompromised States

- Patients with weakened immune systems are at a much higher risk for developing mucormycosis.

This includes individuals with:

- Hematological malignancies (e.g., leukemia, lymphoma), particularly those undergoing chemotherapy or bone marrow suppression.
- Organ transplant recipients (especially kidney, liver, heart, and lung transplants), due to immunosuppressive therapy used to prevent transplant rejection.
- Solid organ transplants: Use of immunosuppressive drugs like corticosteroids, tacrolimus, and cyclosporine.
- HIV/AIDS (with advanced immunosuppression) — although less commonly than other causes of opportunistic infections.

3. Corticosteroid Use

- Corticosteroids and other immunosuppressive medications (e.g., TNF inhibitors) significantly impair the body's immune defense mechanisms.
- Chronic use of steroids (especially in high doses) suppresses the function of T-cells and macrophages, which are crucial for controlling fungal infections.
- Corticosteroid use is common in patients with autoimmune diseases, organ transplants, and chronic inflammatory conditions.

4. Neutropenia

- Neutropenia (low neutrophil count) is a key risk factor for fungal infections, including mucormycosis.
- Chemotherapy for cancer, especially hematologic malignancies like leukemia and

lymphoma, can lead to prolonged neutropenia, which leaves the body unable to mount an effective immune response to fungal spores.
- Bone marrow disorders or stem cell transplants also contribute to neutropenia, increasing susceptibility.

5. Chronic Kidney Disease (CKD) and Dialysis

- Patients with chronic kidney disease (CKD) or those undergoing dialysis are at higher risk of mucormycosis.
- Diabetes and poorly controlled blood sugar are common comorbidities in these patients, further compounding the risk.
- Dialysis procedures, particularly hemodialysis, can create direct access points for fungal spores, and dialysis-related infections are a concern.

6. Trauma, Burns, and Surgical Wounds

- Direct inoculation of fungal spores through trauma, surgery, or burns can lead to cutaneous mucormycosis.
- Skin wounds, including post-surgical wounds, are a common route for fungi to enter the body.
- Intravenous drug use (especially with unsterilized needles) can also introduce fungal spores into the skin or bloodstream.

7. Prematurity and Neonatal Conditions

- Premature infants and neonates with underdeveloped immune systems are highly vulnerable to mucormycosis, especially in the gastrointestinal and cutaneous forms.
- These infants are often exposed to invasive procedures and have weakened skin and mucosal barriers, making them more susceptible to fungal infections.

8. High Iron Levels (Iron Overload)

- Iron overload or increased iron availability is a known risk factor for mucormycosis, as these fungi require iron for growth.
- Conditions that cause elevated iron levels include:
- Hemochromatosis (a genetic disorder causing excessive iron absorption).
- Frequent blood transfusions (in patients with thalassemia, sickle cell disease, or other hematologic disorders).
- Iron supplementation in certain patients, particularly those with chronic anemia or CKD.

9. Cancer (Especially Hematologic Malignancies)

- Hematologic cancers, such as leukemia and lymphoma, are among the most significant risk factors for mucormycosis, particularly during chemotherapy and in patients with neutropenia.
- Solid tumors and chemotherapy treatments can also increase susceptibility to mucormycosis, especially if the immune system is compromised.

10. Malnutrition

- Malnutrition or severe cachexia (wasting syndrome) can weaken the immune system, making it harder for the body to fight off infections, including mucormycosis.
- Vitamin D deficiency and other micronutrient deficiencies can impair immune responses and predispose individuals to fungal infections.

Pathophysiology:

The pathophysiology of mucormycosis involves a complex interplay between the Mucorales fungi, the host's immune response, and various predisposing factors. These fungi, including

species like Rhizopus, Mucor, Lichtheimia, and others, are typically opportunistic pathogens that cause infections primarily in individuals with immunocompromised states or underlying conditions. The pathogenesis is driven by the inhalation of fungal spores (conidia), their germination, and subsequent invasive growth, leading to tissue necrosis, dissemination, and potentially systemic infection.

Overview of Key Steps in Pathophysiology

1. Entry and Germination of Spores

- Mucorales fungi exist in the environment as spores (conidia), which are highly resistant to environmental stressors. These spores can be inhaled into the lungs, inoculated into the skin via trauma or burns, or reach the gastrointestinal tract.
- Upon entering the body, the spores encounter various host tissues, especially mucosal surfaces (e.g., nasal cavity, sinuses, lungs, gastrointestinal tract) or broken skin.
- The spores then germinate and form hyphae (long, branching, non-septate filaments). The germination is often stimulated by environmental conditions such as high glucose levels (e.g., in diabetes), low pH (in acidosis), or tissue damage.

2. Angioinvasion

- Mucorales fungi are angioinvasive, meaning they invade blood vessels as part of their pathogenesis. The hyphae of the fungi penetrate the walls of blood vessels, disrupting the endothelial lining and leading to thrombosis (clot formation).
- This process impairs blood flow to surrounding tissues, resulting in ischemia (reduced blood supply) and tissue necrosis.
- The combination of vascular invasion and tissue ischemia leads to widespread tissue destruction, particularly in organs like the sinuses, lungs, and brain.

3. Immune Evasion

- The immune system typically responds to fungal infections by activating phagocytic cells (e.g., neutrophils and macrophages) that attempt to engulf and kill the invading fungi. However, Mucorales have developed several mechanisms to evade these immune defenses:
- Inhibition of phagocytosis: Mucorales produce surface proteins (e.g., hydrophobins) that help them resist being engulfed by phagocytes.
- Iron acquisition: The fungi secrete siderophores, molecules that bind and sequester iron from the host. Since iron is essential for fungal growth, Mucorales can outcompete the host for this critical nutrient.
- Resistance to oxidative stress: Mucorales are capable of surviving and growing in the presence of reactive oxygen species (ROS) generated by phagocytes during an immune response. This allows them to persist despite attempts by immune cells to destroy them.

4. Tissue Necrosis and Inflammation

- The invasive hyphal growth causes direct tissue damage. The hyphae not only invade blood vessels but also extend through tissues like muscle, fat, and nerves, leading to necrosis (death of cells and tissues).
- The inflammatory response initiated by the host to control the infection leads to the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6), which contribute to swelling, pain, and tissue destruction.
- As tissue death progresses, black necrotic tissue becomes visible, especially in rhinocerebral mucormycosis, where the nose,

palate, or sinuses become discolored due to ischemia and necrosis.

5. Dissemination and Systemic Infection

- The infection can spread from the primary site (e.g., sinuses or skin) to other parts of the body via the bloodstream. This is known as disseminated mucormycosis, which is most common in immunocompromised individuals.
- Once the fungi invade the bloodstream (via angioinvasion), they can spread to multiple organs including the brain, lungs, kidneys, heart, and gastrointestinal tract. The brain is particularly vulnerable to infection, resulting in rhinocerebral mucormycosis that can cause severe neurological symptoms and coma.

6. Clinical Manifestations

As the infection becomes more invasive, symptoms worsen rapidly, including:

- Fever, chills, and signs of systemic infection.
- Respiratory distress in pulmonary mucormycosis, with cough, hemoptysis, and shortness of breath.
- Neurological symptoms (headache, confusion, seizures) if the infection involves the brain.
- Gastrointestinal symptoms (abdominal pain, nausea, vomiting) if the gastrointestinal tract is involved.

Diagnosis

The diagnosis of mucormycosis is a challenging process that requires a high index of suspicion, especially since the disease can progress rapidly and may be mistaken for other conditions. A combination of clinical evaluation, microbiological testing, and imaging studies is essential for accurate diagnosis. Early identification and treatment are crucial for improving outcomes, as mucormycosis has a high mortality rate if not treated promptly.

Here's a detailed look at the steps involved in diagnosing mucormycosis:

1. Clinical Suspicion

The diagnosis of mucormycosis begins with clinical suspicion, based on symptoms, patient history, and risk factors. Key clues include:

- Rapidly progressing tissue necrosis (e.g., facial swelling, black nasal discharge, skin ulcers).
- Fever, pain, headache, and symptoms of sinusitis or cerebral involvement (confusion, seizures). - Presence of risk factors such as uncontrolled diabetes mellitus, immunosuppressive therapy, hematologic malignancies, or organ transplantation.
- Symptoms depending on the site of infection (e.g., pulmonary mucormycosis presenting with cough, hemoptysis, and respiratory distress).

2. Microbiological Diagnosis

Once mucormycosis is suspected, microbiological testing plays a critical role in confirming the diagnosis.

A. Direct Microscopic Examination

- Tissue samples are obtained from the suspected infection site (e.g., nasal swabs, biopsy of skin lesions, sputum, bronchoalveolar lavage for pulmonary involvement).
- KOH preparation: A tissue sample is stained with potassium hydroxide (KOH) and examined under a microscope. The characteristic findings include:
- Non-septate (aseptate) hyphae with right-angle branching (usually at 90 degrees).

- Thick-walled hyphae that may appear broad and ribbon-like, indicative of mucor species.

B. Histopathological Examination

Biopsy specimens (e.g., skin, sinuses, lung tissue) are often collected for histological examination.

- The key histopathological features include:
- Invasive hyphae with angioinvasion (blood vessel invasion).
- Tissue necrosis and thrombosis due to fungal vascular invasion.
- Black necrotic tissue is often seen in rhinocerebral mucormycosis.

C. Fungal Culture

- Fungal cultures from the clinical sample (e.g., blood, sputum, tissue biopsy) can confirm the presence of Mucorales.
- Mucorales typically grow rapidly on sabouraud dextrose agar at 25–30°C and often form cottony, woolly, or fuzzy colonies.
- Rhizopus species may appear white initially and turn dark brown or black as they mature.
- Note: Culture is not always positive, especially if the patient is on antifungal treatment or if tissue damage prevents fungal growth in the sample.

D. Polymerase Chain Reaction (PCR)

- PCR testing for Mucorales DNA is a more sensitive method and can be used to detect fungal DNA in clinical specimens like blood, sputum, or tissue.
- PCR can identify specific fungal species and confirm the diagnosis more quickly than culture- base[[[[d methods.

E. Serologic Testing

- Serologic tests (e.g., for antibodies against mucormycosis) are generally not helpful for diagnosing mucormycosis because they are not widely available and do not provide timely results.
- Antigen detection methods are also not commonly used in clinical practice, though research is ongoing to develop reliable serological tests.

3. Imaging Studies

Imaging plays a key role in identifying the extent of infection, guiding biopsy procedures, and assessing complications like vascular invasion and tissue necrosis.

A. CT Scan (Computed Tomography)

- Chest CT: In pulmonary mucormycosis, CT imaging can show:
- Lobar consolidation, cavitary lesions, or nodules.
- Air bronchogram (indicating air-filled bronchi surrounded by consolidation).
- Hematogenous dissemination with multiple lung nodules, which can help detect systemic spread.
- "Reverse halo sign" (also called atoll sign): A ring-like consolidation with a clear center, seen in some cases of pulmonary mucormycosis.
- Sinus CT/MRI: In rhinocerebral mucormycosis, imaging is crucial for assessing:
- Sinus involvement: Sinus opacification, air-fluid levels, or bone destruction.
- Orbital invasion: Orbital abscesses, proptosis (bulging eyes), and extensive orbital or facial bone destruction.
- Intracranial extension: Fungal invasion can cause cerebral abscesses and infarcts, detectable on MRI or CT of the brain.

B. MRI

- MRI is particularly useful for brain involvement (in rhinocerebral mucormycosis).
- T1-weighted MRI shows hypointense (dark) lesions in the affected areas (due to necrosis).
- T2-weighted MRI shows hyperintense lesions in the infected areas.
- MRI is useful for identifying cerebral abscesses, thrombosis, and edema caused by fungal infection.

C. Angiography (for Disseminated Disease)

- Angiography (e.g., CT angiography or MRI angiography) may be used to assess vascular involvement or thrombosis caused by fungal invasion, particularly in disseminated mucormycosis.

4. Blood Tests

While blood cultures for Mucorales are typically negative, some blood tests may offer supportive information or help in monitoring the disease:

- Elevated inflammatory markers: C-reactive protein (CRP), white blood cell count, and erythrocyte sedimentation rate (ESR) are often elevated in infection.
- Liver and kidney function tests: These may be abnormal if the infection has spread to internal organs, such as the liver or kidneys.
- Fungal biomarkers: Though not specific for mucormycosis, some research is exploring fungal biomarkers like (1→3)-β-D-glucan for early detection of fungal infections. However, these are not routinely used for mucormycosis.

Treatments

The treatment of mucormycosis requires a multidisciplinary approach involving antifungal therapy, surgical intervention, and addressing underlying risk factors. Mucormycosis is a rapidly progressing and often life-threatening infection, so prompt treatment is essential for improving outcomes. The overall approach to treatment is typically divided into the following components:

1. Antifungal Therapy

The cornerstone of medical management of mucormycosis is the use of antifungal medications. Treatment often needs to be initiated empirically while awaiting the results of microbiological testing, and the choice of antifungal agent is based on fungal species and severity of infection.

A. First-line Antifungal Agents

Amphotericin B is the first-line antifungal treatment for mucormycosis.

- Liposomal amphotericin B (L-AmB) is preferred over conventional amphotericin B due to its improved pharmacokinetics, lower toxicity, and better tissue penetration, especially in immunocompromised patients.
- Dose: The typical starting dose of liposomal amphotericin B is 5 mg/kg/day. This may be adjusted based on response, toxicity, and renal function.
- Duration: Treatment duration varies but often lasts 4–6 weeks or longer, depending on clinical response and infection site.

B. Other Amphotericin B Formulations

- Conventional amphotericin B is sometimes used if liposomal amphotericin is not available, but it has a higher risk of nephrotoxicity and infusion-related reactions. Dosage is typically 0.5–1 mg/kg/day intravenously.

C. Posaconazole

- Posaconazole (an azole antifungal) is used as second-line or adjunctive therapy, particularly for patients who cannot tolerate amphotericin B or for maintenance therapy after initial therapy with amphotericin B.
- Oral form is commonly used as it achieves good tissue penetration.
- Dose: The recommended dose is typically 200 mg orally twice a day for the first day, followed by 200 mg once a day.

D. Isavuconazole

- Isavuconazole is another newer triazole antifungal with activity against Mucorales and is approved for the treatment of invasive aspergillosis and mucormycosis. It is an alternative to posaconazole.
- Isavuconazole offers a more convenient oral formulation and fewer side effects than other agents. - Dose: The typical dose is 200 mg every 8 hours for the first 48 hours, followed by 200 mg daily.

E. Combination Therapy

- In severe cases, combination therapy with both amphotericin B and posaconazole or isavuconazole may be considered, though the evidence for improved outcomes with combination therapy is still limited.

F. Emerging Therapies

- Echinocandins (e.g., caspofungin, micafungin) have limited activity against Mucorales, but they are sometimes considered in refractory cases or as part of combination therapy. However, their efficacy is not as well established as that of amphotericin B.

2. Surgical Treatment

Surgical debridement is critical in the management of mucormycosis, especially for infections in sinuses, skin, or lungs. Fungus is often deeply embedded in tissues, and antifungal therapy alone is insufficient for controlling the infection.

A. Necrotic Tissue Debridement

- Aggressive debridement of necrotic and infected tissue is required to control the infection, prevent further spread, and reduce the fungal burden.
- In rhinocerebral mucormycosis, this may involve sinus surgery and excision of necrotic tissue in the orbit, palate, or brain.
- In pulmonary mucormycosis, surgical removal of necrotic lung tissue or lung resection may be necessary in cases of cavitary lesions or extensive involvement.

B. Amputation (for severe cases)

- In cases of extensive tissue necrosis (e.g., in patients with diabetic foot infections), amputation of the affected limb may be required to save the patient's life.

C. Orbital Decompression

- In orbital mucormycosis with involvement of the eye, orbital decompression surgery may be necessary to remove infected tissue, including the orbital contents (e.g., eyeball) in severe cases.

3. Management of Underlying Conditions

Managing underlying risk factors is a key aspect of treatment. Correction of the predisposing factors can help improve the patient's immune response and reduce the risk of further fungal infections.

A. Diabetes Management

- Optimizing blood glucose control is critical, particularly for patients with diabetes mellitus (especially those with diabetic ketoacidosis).
- Insulin therapy should be adjusted to maintain euglycemia.
- Ketone management in cases of diabetic ketoacidosis (DKA) is crucial to reverse the acidotic state and prevent exacerbation of the fungal infection.

B. Immunosuppressive Therapy

- For patients with a history of organ transplantation or hematologic malignancies, reducing or modifying immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may help improve immune function. However, this must be done carefully and under medical supervision to avoid rejection of transplanted organs or worsening of the underlying malignancy.

C. Management of Neutropenia

- If the patient has neutropenia (low neutrophil count), granulocyte colony-stimulating factors (G-CSF) may be considered to stimulate neutrophil recovery, especially in patients with hematologic malignancies undergoing chemotherapy.

4. Supportive Care

- Supportive care is essential, particularly for patients who are critically ill, require intensive care, or are undergoing invasive surgeries.
- Intensive Care: Some patients may require ventilatory support, vasopressors, or renal replacement therapy (e.g., hemodialysis) due to multiorgan failure, sepsis, or acute kidney injury.
- Nutrition Support: Ensuring adequate nutrition is vital, especially in patients with extensive tissue necrosis or following major surgeries.
- Pain Management: Pain relief is a critical aspect of supportive care, particularly for patients undergoing extensive debridement or suffering from severe tissue damage.

6. Prognosis

The prognosis of mucormycosis largely depends on several factors:

- Timeliness of diagnosis and treatment.
- Extent of infection (localized vs. disseminated).
- Immune status of the patient (e.g., diabetic ketoacidosis, immunosuppression).
- Site of infection (e.g., rhinocerebral mucormycosis and pulmonary mucormycosis can have better outcomes if diagnosed early, whereas disseminated mucormycosis has a poor prognosis).

Drug Profile of Amphotericin B:

Mol wt-924.079g/mol Mol formula-C47H73NO17 B.P-804.34°C. M.P-170°C

Amphotericin B is one of the cornerstone treatments for mucormycosis, a severe and often rapidly progressive fungal infection caused by members of the Mucoraceae family. It is a broad-spectrum antifungal agent with potent activity against various fungal species, including Mucor, Rhizopus, and Absidia, which are the most common causes of mucormycosis.

1. Mechanism of Action:

- Amphotericin B binds to ergosterol, a crucial component of the fungal cell membrane. This binding disrupts the integrity of the fungal cell membrane, leading to increased membrane permeability and the leakage of intracellular contents, resulting in fungal cell death.

- It is fungicidal (kills the fungi), particularly effective against fungi with a high ergosterol content, such as mucormycetes.



2. Pharmacokinetics:

- Absorption:
- Amphotericin B is poorly absorbed from the gastrointestinal tract, which is why it is typically administered intravenously for systemic infections.
- Distribution:
- It has a wide distribution throughout the body, including tissues like the lungs, liver, kidneys, brain, and spleen.
- It has a high protein binding capacity (about 90–95%).
- Metabolism:
- Amphotericin B is minimally metabolized in the liver, and its breakdown is not significant in the body. Its primary mechanism of clearance is through the kidneys.
- Elimination:
- The drug is primarily excreted unchanged in the urine, with a half-life of approximately 24 hours for conventional formulations. However, liposomal formulations may have different pharmacokinetics, with a longer half-life.

3. Formulations of Amphotericin B:

There are several formulations of amphotericin B, and their selection depends on factors like side effect profile, severity of infection, and cost. These formulations include:

- Conventional Amphotericin B (Deoxycholate):
- The standard formulation of amphotericin B, which is highly effective but has significant toxicities.
- Liposomal Amphotericin B:
- Liposomal encapsulation of amphotericin B reduces its toxicity by altering its distribution, allowing it to concentrate more effectively in fungal tissue while reducing exposure to kidneys and other organs.
- This formulation is commonly used in severe cases of mucormycosis and in patients with renal impairment.

- Lipid Complex Amphotericin B (Abelcet®):
- Similar to liposomal amphotericin B but with different lipid encapsulation, also designed to reduce nephrotoxicity.
- Amphotericin B Colloidal Dispersion (Amphotec®):
- Another lipid-based formulation designed to reduce toxicity, though less commonly used compared to liposomal forms.

4. Indications for Use in Mucormycosis:

- First-line therapy for systemic mucormycosis. It is used in the treatment of all forms of mucormycosis, including:
- Rhinocerebral mucormycosis (sinus, orbital, and brain involvement)
- Pulmonary mucormycosis
- Gastrointestinal mucormycosis
- Cutaneous mucormycosis
- Disseminated mucormycosis (when the infection spreads to multiple organs)
- It is the preferred treatment for severe, invasive mucormycosis in immunocompromised patients (e.g., those with diabetic ketoacidosis, neutropenia, hematologic malignancies, and organ transplants).

5. Dosing and Administration:

Conventional Amphotericin B:

- Initial dose: 0.5 to 1 mg/kg/day (IV) for the first few days, gradually increasing to 1–1.5 mg/kg/day.
- Maintenance dose: Once the patient is stabilized, the dose is often reduced to 0.5–1 mg/kg/day.
- Liposomal Amphotericin B:
- Initial dose: 5 mg/kg/day (IV) is commonly used for mucormycosis.
- The dose can be adjusted based on the patient's response and tolerability, but higher doses may be required for more severe infections.

Duration of Treatment:

- The duration of treatment typically ranges from 4 to 6 weeks or until clinical resolution, which is often extended in patients with severe disease or poor response.
- Therapy should continue for several weeks, and in some cases, lifelong therapy may be necessary in patients with persistent immune compromise.

CONCLUSION:

Mucormycosis is a serious, rapidly progressing fungal infection caused by the Mucorales family of fungi, which primarily affects immunocompromised individuals, including those with diabetes mellitus, hematologic malignancies, organ transplants, and severe trauma. The infection can lead to devastating complications, including tissue necrosis, vascular invasion, and dissemination to critical organs (e.g., brain, lungs, heart), often resulting in high morbidity and mortality if not diagnosed and treated promptly. The management of mucormycosis requires a multidisciplinary approach that combines aggressive antifungal therapy, surgical debridement, and careful management of underlying conditions. Early diagnosis is crucial and relies on a combination of clinical suspicion, microbiological testing, and imaging. Early intervention can improve survival rates significantly, but the disease's rapid progression means that diagnosis is often made in advanced stages, complicating treatment. Antifungal therapy with liposomal amphotericin B is the mainstay of treatment, though posaconazole and isavuconazole are emerging as alternatives, particularly for maintenance therapy or for patients unable to

tolerate amphotericin B. The choice of antifungal and treatment duration is guided by the severity of the infection and the patient's overall health. Surgical debridement of necrotic tissue is essential to control the spread of the infection and reduce fungal burden, especially for infections involving the sinuses, lungs, skin, and orbit. In some cases, more extensive procedures, such as amputation or orbital decompression, may be necessary to save life and preserve function.

REFERENCES

1. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, nonRhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–445. [PubMed: 21482731]
2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236–301. [PubMed: 10756000]
3. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. [PubMed: 16080086]
4. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31–47. [PubMed: 14748801]
5. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the Retro Zygo Study (2005–2007). Clin Infect Dis. 2012;54 Suppl 1:S35–43. [PubMed: 22247443] 6. Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335–342. [PubMed: 16772227]
6. Walther G, Wagner L, Kurzai O. Updates on the Taxonomy of Mucorales with an Emphasis on Clinically Important Taxa. J Fungi (Basel). 2019;5(4).
7. Orlowski M Mucor dimorphism. Microbiol Rev. 1991;55(2):234–258. [PubMed: 1886520] 9. Steinberg G, Peñalva MA, Riquelme M, Wösten HA, Harris SD. Cell Biology of Hyphal Growth. Microbiol Spectr. 2017;5(2).
8. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34. [PubMed: 30036666]
9. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17(10):1855–1864. [PubMed: 22000355]
10. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293–300. [PubMed: 22789847]
11. Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16(1):730. [PubMed: 27905900]
12. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32(9):1319–1324. [PubMed: 11303267]
13. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary- care cancer center. Clin Infect Dis. 2000;30(6):851–856. [PubMed: 10852735]
14. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary

transplant center and review of the literature. Am J Transplant. 2006;6(10):2365–2374. [PubMed: 16925570]

15. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–1100. [PubMed: 20218877] cases. J Infect Dis. 2005;191(8):1350–1360. [PubMed: 15776383].

HOW TO CITE: Sonkamble Sumed, Devshatwar Radhika*, Jamadar Amrata, Kamshette Arati, Akuch Sandhya, Survase Mohini, Clinical Review on Mucormycosis, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 4, 752-769 https://doi.org/10.5281/zenodo.15166601